{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:04:16Z","timestamp":1785409456047,"version":"3.56.0"},"reference-count":35,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline"},{"id":[{"id":"https:\/\/ror.org\/025vn3989","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Patients with myeloproliferative neoplasms (MPN) are at increased risk of herpes zoster, particularly during Janus kinase inhibitor (JAKi) therapy, yet the immunogenicity of recombinant zoster vaccine (RZV) in this setting remains incompletely characterized. We performed a prospective pilot translational study including 18 patients with MPN and a small age-matched healthy donor group (n = 4, descriptive reference only). Samples were collected at baseline, 21 days after the first dose, and 21 days after the second dose. Humoral response was assessed by anti-varicella-zoster virus (VZV) immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA), whereas antigen-specific cellular responses were evaluated after ex vivo stimulation with recombinant VZV glycoprotein E followed by flow cytometry and cytokine quantification. IgG levels increased over time in MPN patients, while cellular responses remained limited, heterogeneous, and not consistently enhanced. Cytokine production was low and variable across time points. Overall, RZV in MPN under JAKi was associated with detectable humoral responses but limited cellular activation, supporting an apparent discordance between humoral and cellular immune readouts under the experimental conditions used.<\/jats:p>","DOI":"10.3390\/ijms27125543","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:37:42Z","timestamp":1781879862000},"page":"5543","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dissociated Humoral and Cellular Immune Responses to Recombinant Zoster Vaccine in Myeloproliferative Neoplasms Under JAK Inhibition: A Pilot Study"],"prefix":"10.3390","volume":"27","author":[{"given":"Julio","family":"Torres-Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"BE21-Hematolog\u00eda e Inmunoterapia, IBIMA Plataforma BIONAND, Avenida Severo Ochoa 35, 29590 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5295-4062","authenticated-orcid":false,"given":"Blanca","family":"O\u2019Donnell-Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Departamento de Salud P\u00fablica y Psiquiatr\u00eda, Universidad de M\u00e1laga, 29010 M\u00e1laga, Spain"},{"name":"\u00c1rea A-23 Medicina Preventiva y Salud P\u00fablica, IBIMA Plataforma BIONAND, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga, Avenida Severo Ochoa 35, 29590 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-0161","authenticated-orcid":false,"given":"Rodolfo Mat\u00edas","family":"Ortiz-Flores","sequence":"additional","affiliation":[{"name":"BE21-Hematolog\u00eda e Inmunoterapia, IBIMA Plataforma BIONAND, Avenida Severo Ochoa 35, 29590 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz Piotr Narankiewicz","family":"Talarczyk","sequence":"additional","affiliation":[{"name":"\u00c1rea A-23 Medicina Preventiva y Salud P\u00fablica, IBIMA Plataforma BIONAND, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga, Avenida Severo Ochoa 35, 29590 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Cidoncha-Morcillo","sequence":"additional","affiliation":[{"name":"UGC Hematolog\u00eda y Hemoterapia, Hospital Universitario Virgen de la Victoria, Campus de Teatinos, s\/n, 29010 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Fari\u00f1as-Guerrero","sequence":"additional","affiliation":[{"name":"Instituto de Hematolog\u00eda, Inmunolog\u00eda y Biolog\u00eda M\u00e9dica Avanzada (HEMOINMUN), 29590 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Rodr\u00edguez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"UGC Hematolog\u00eda y Hemoterapia, Hospital Universitario Virgen de la Victoria, Campus de Teatinos, s\/n, 29010 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Garc\u00eda-Delgado","sequence":"additional","affiliation":[{"name":"BE21-Hematolog\u00eda e Inmunoterapia, IBIMA Plataforma BIONAND, Avenida Severo Ochoa 35, 29590 M\u00e1laga, Spain"},{"name":"UGC Hematolog\u00eda y Hemoterapia, Hospital Universitario Virgen de la Victoria, Campus de Teatinos, s\/n, 29010 M\u00e1laga, Spain"},{"name":"Departamento de Fisiolog\u00eda Humana, Histolog\u00eda Humana, Anatom\u00eda Patol\u00f3gica y Educaci\u00f3n F\u00edsico-Deportiva, Facultad de Medicina, Universidad de M\u00e1laga, Boulevard Louis Pasteur 32, 29010 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9135-5330","authenticated-orcid":false,"given":"Alejandro","family":"Escamilla-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"BE21-Hematolog\u00eda e Inmunoterapia, IBIMA Plataforma BIONAND, Avenida Severo Ochoa 35, 29590 M\u00e1laga, Spain"},{"name":"Departamento de Fisiolog\u00eda Humana, Histolog\u00eda Humana, Anatom\u00eda Patol\u00f3gica y Educaci\u00f3n F\u00edsico-Deportiva, Facultad de Medicina, Universidad de M\u00e1laga, Boulevard Louis Pasteur 32, 29010 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Patil, A., Goldust, M., and Wollina, U. (2022). Herpes zoster: A review of clinical manifestations and management. Viruses, 14.","DOI":"10.3390\/v14020192"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Laemmle, L., Goldstein, R.S., and Kinchington, P.R. (2019). Modeling varicella zoster virus persistence and reactivation. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.01634"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.37201\/req\/004.2023","article-title":"Status of herpes zoster and herpes zoster vaccines in 2023: A position paper","volume":"36","year":"2023","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","article-title":"Advances in the understanding of the pathogenesis and epidemiology of herpes zoster","volume":"48","author":"Gershon","year":"2010","journal-title":"J. Clin. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: Herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e793","DOI":"10.1097\/HS9.0000000000000793","article-title":"High incidence of herpes zoster in patients using ruxolitinib for myeloproliferative neoplasms: Need for prophylaxis","volume":"6","author":"Boots","year":"2022","journal-title":"HemaSphere"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/0008-5472.CAN-21-2930","article-title":"Myelofibrosis: Genetic characteristics and the emerging therapeutic landscape","volume":"82","author":"Tefferi","year":"2022","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12964-023-01240-y","article-title":"Double-edged sword of JAK\/STAT signaling pathway in viral infections: Novel insights into virotherapy","volume":"21","author":"Mahjoor","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Elli, E.M., Barat\u00e8, C., Mendicino, F., Palandri, F., and Palumbo, G.A. (2019). Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01186"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Cattaneo, D., and Iurlo, A. (2021). Immune dysregulation and infectious complications in MPN patients treated with JAK inhibitors. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.750346"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.reuma.2021.06.004","article-title":"JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis: Systematic review of the literature","volume":"18","year":"2022","journal-title":"Reumatol. Clin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/bjc.2017.124","article-title":"Herpes zoster risk after 21 specific cancers: Population-based case-control study","volume":"116","author":"Hansson","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Xu, Q., He, L., and Yin, Y. (2023). Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: A systematic review and network meta-analysis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1241954"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13373","article-title":"JAK1\/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms","volume":"169","author":"Cornez","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coi.2019.02.009","article-title":"Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine","volume":"59","author":"Heineman","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"npj Vaccines"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e175378","DOI":"10.1172\/JCI175378","article-title":"Advances in understanding the mechanism of action of adult vaccines","volume":"133","author":"Cunningham","year":"2023","journal-title":"J. Clin. Invest."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: Helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: A phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: A randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: A phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/cncr.31909","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial","volume":"125","author":"Vink","year":"2019","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1080\/21645515.2021.1953346","article-title":"Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: Polyfunctional immune responses and lessons for clinical practice","volume":"17","author":"Stadtmauer","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Marra, F., Yip, M., Cragg, J.J., and Vadlamudi, N.K. (2024). Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0313889"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7273","DOI":"10.1182\/blood-2025-7273","article-title":"The recombinant adjuvant zoster vaccine induces similar immune responses in ruxolitinib-treated patients with myelofibrosis and polycythemia vera","volume":"146","author":"Leguizamon","year":"2025","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","article-title":"JAK inhibition impairs NK cell function in myeloproliferative neoplasms","volume":"75","author":"Rudolph","year":"2015","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41408-022-00651-3","article-title":"Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib","volume":"12","author":"Harrington","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41375-020-01074-4","article-title":"Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma","volume":"35","author":"Zent","year":"2021","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.vaccine.2022.10.063","article-title":"Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions","volume":"41","author":"Sullivan","year":"2023","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Delgado, R., Luque-Lupi\u00e1\u00f1ez, E., Mora-Infante, D., Ortiz-Flores, R.M., Cidoncha-Morcillo, B., Torres-Gonz\u00e1lez, J., Fontalba-Navas, A., and Escamilla-S\u00e1nchez, A. (2025). Translational insights into interferon alpha\u2019s effects on immunomolecular dynamics in Philadelphia-negative myeloproliferative neoplasms. Cancers, 17.","DOI":"10.3390\/cancers17142273"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5543\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:50:16Z","timestamp":1782535816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27125543"],"URL":"https:\/\/doi.org\/10.3390\/ijms27125543","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]}}}